27799314|t|IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7 / 8 Agonist R848 (Resiquimod)
27799314|a|Different models of experimental allergic asthma have shown that the TLR7 / 8 agonist resiquimod (R848) is a potential inhibitor of type 2 helper cell -driven inflammatory responses. However, the mechanisms mediating its therapeutic effects are not fully understood. Using a model of experimental allergic asthma, we show that induction of IL-27 by R848 is critical for the observed ameliorative effects. R848 significantly inhibited all hallmarks of experimental allergic asthma, including airway hyperreactivity, eosinophilic airway inflammation, mucus hypersecretion, and Ag - specific Ig production. Whereas R848 significantly reduced IL-5, IL-13, and IL-17, it induced IFN-γ and IL-27. Neutralization of IL-27 completely reversed the therapeutic effect of R848 in the experimental asthma model, demonstrating dependence of R848 -mediated suppression on IL-27. In vitro, R848 induced production of IL-27 by murine alveolar macrophages and dendritic cells and enhanced expression of programmed death-ligand 1, whose expression on monocytes and dendritic cells has been shown to regulate peripheral tolerance in both murine and human studies. Moreover, in vitro IL-27 enhanced secretion of IFN-γ whereas it inhibited IL-5 and IL-13, demonstrating its direct effect on attenuating Th2 responses. Taken together, our study proves that R848 -mediated suppression of experimental asthma is dependent on IL-27. These data provide evidence of a central role of IL-27 for the control of Th2 -mediated allergic diseases.
27799314	0	5	IL-27	T116,T129	C1706289
27799314	23	34	Suppression	T061	C0021079
27799314	38	50	Experimental	T080	C1517586
27799314	51	66	Allergic Asthma	T047	C0155877
27799314	74	78	TLR7	T116,T129,T192	C1579758
27799314	81	82	8	T116,T192	C1579755
27799314	83	90	Agonist	T121	C2987634
27799314	91	95	R848	T109,T121	C3642356
27799314	97	107	Resiquimod	T109,T121	C0965594
27799314	119	141	models of experimental	T050	C0684309
27799314	142	157	allergic asthma	T047	C0155877
27799314	178	182	TLR7	T116,T129,T192	C1579758
27799314	185	186	8	T116,T192	C1579755
27799314	187	194	agonist	T121	C2987634
27799314	195	205	resiquimod	T109,T121	C0965594
27799314	207	211	R848	T109,T121	C3642356
27799314	228	237	inhibitor	T080	C1999216
27799314	241	259	type 2 helper cell	T025	C0242633
27799314	268	290	inflammatory responses	T046	C1155266
27799314	330	349	therapeutic effects	T201	C1527144
27799314	384	405	model of experimental	T050	C0684309
27799314	406	421	allergic asthma	T047	C0155877
27799314	436	445	induction	T061	C0857127
27799314	449	454	IL-27	T116,T129	C1706289
27799314	458	462	R848	T109,T121	C3642356
27799314	492	504	ameliorative	T080	C0332272
27799314	514	518	R848	T109,T121	C3642356
27799314	533	542	inhibited	T080	C0311403
27799314	547	556	hallmarks	T025	C1512330
27799314	560	572	experimental	T080	C1517586
27799314	573	588	allergic asthma	T047	C0155877
27799314	600	622	airway hyperreactivity	T047	C0004096
27799314	624	636	eosinophilic	T169	C0333930
27799314	637	643	airway	T023	C0458827
27799314	644	656	inflammation	T046	C0021368
27799314	658	678	mucus hypersecretion	T047	C0155872
27799314	684	686	Ag	T129	C0003320
27799314	689	700	specific Ig	T116,T121,T129	C0358334
27799314	701	711	production	T038	C0003261
27799314	721	725	R848	T109,T121	C3642356
27799314	748	752	IL-5	T116,T129	C0021759
27799314	754	759	IL-13	T116,T129	C0214743
27799314	765	770	IL-17	T116,T129	C0384648
27799314	783	788	IFN-γ	T116,T121,T129	C3539881
27799314	793	798	IL-27	T116,T129	C1706289
27799314	800	814	Neutralization	T169	C2987668
27799314	818	823	IL-27	T116,T129	C1706289
27799314	848	866	therapeutic effect	T201	C1527144
27799314	870	874	R848	T109,T121	C3642356
27799314	882	894	experimental	T080	C1517586
27799314	895	901	asthma	T047	C0004096
27799314	902	907	model	T050	C0684309
27799314	937	941	R848	T109,T121	C3642356
27799314	952	963	suppression	T061	C0021079
27799314	967	972	IL-27	T116,T129	C1706289
27799314	974	982	In vitro	T080	C1533691
27799314	984	988	R848	T109,T121	C3642356
27799314	989	996	induced	T061	C0857127
27799314	1011	1016	IL-27	T116,T129	C1706289
27799314	1020	1026	murine	T015	C0026809
27799314	1027	1047	alveolar macrophages	T025	C0085236
27799314	1052	1067	dendritic cells	T025	C0011306
27799314	1072	1080	enhanced	T052	C2349975
27799314	1081	1091	expression	T045	C1171362
27799314	1095	1120	programmed death-ligand 1	T129	C4300350
27799314	1128	1138	expression	T045	C1171362
27799314	1142	1151	monocytes	T025	C0085236
27799314	1156	1171	dendritic cells	T025	C0011306
27799314	1190	1198	regulate	T038	C1327622
27799314	1199	1219	peripheral tolerance	T042	C3179073
27799314	1228	1234	murine	T015	C0026809
27799314	1239	1244	human	T016	C0086418
27799314	1264	1272	in vitro	T080	C1533691
27799314	1273	1278	IL-27	T116,T129	C1706289
27799314	1279	1287	enhanced	T052	C2349975
27799314	1288	1297	secretion	T043	C1327616
27799314	1301	1306	IFN-γ	T116,T121,T129	C3539881
27799314	1318	1327	inhibited	T080	C0311403
27799314	1328	1332	IL-5	T116,T129	C0021759
27799314	1337	1342	IL-13	T116,T129	C0214743
27799314	1391	1394	Th2	T025	C0242633
27799314	1444	1448	R848	T109,T121	C3642356
27799314	1459	1470	suppression	T061	C0021079
27799314	1474	1486	experimental	T080	C1517586
27799314	1487	1493	asthma	T047	C0004096
27799314	1510	1515	IL-27	T116,T129	C1706289
27799314	1566	1571	IL-27	T116,T129	C1706289
27799314	1591	1594	Th2	T025	C0242633
27799314	1605	1622	allergic diseases	T047	C1504369